Related Experiment Video

Updated: May 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Shock block for improved immunotherapy

Aparna Rao1, Devin B Lowe, Walter J Storkus

  • 1Department of Immunology; University of Pittsburgh School of Medicine; Pittsburgh, PA USA ; Department of Dermatology; University of Pittsburgh School of Medicine; Pittsburgh, PA USA.

Oncoimmunology
|December 18, 2012
PubMed

Insights

Chemical inhibitors targeting heat shock protein 90 (HSP90) combined with vaccination strategies against HSP90 client proteins improve cancer therapy. This approach enhances therapeutic benefit by targeting tumor-specific proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Heat shock proteins (HSP) are crucial for stabilizing proteins that promote cancer cell growth and survival, including receptor tyrosine kinases (RTKs).
  • Targeting HSP90 offers a potential therapeutic strategy in oncology due to its role in client protein stability.

Purpose of the Study:

  • To investigate the combined therapeutic efficacy of HSP90 inhibitors and a vaccination strategy targeting HSP90 client proteins.
  • To evaluate the impact of this combination therapy on tumors overexpressing specific client proteins.

Main Methods:

  • Utilized chemical HSP90 inhibitors in preclinical cancer models.
  • Developed and applied a vaccination strategy focused on HSP90 client proteins overexpressed in the tumor microenvironment.
  • Assessed the therapeutic benefit and tumor response in vivo.

Main Results:

  • The combination of HSP90 inhibitors and client protein-targeted vaccination demonstrated superior therapeutic benefit compared to monotherapy.
  • This synergistic effect was observed in tumors characterized by the overexpression of specific HSP90 client proteins.
  • The strategy effectively targeted essential proteins for cancer cell growth and survival.

Conclusions:

  • Combining HSP90 inhibition with targeted vaccination represents a promising strategy for enhancing cancer treatment outcomes.
  • This approach holds potential for treating cancers reliant on specific HSP90 client proteins for survival.
  • Further research into combination therapies targeting HSP-client protein interactions is warranted.

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.